Bright Minds Biosciences reports FDA partial hold on BMB‑101 seizure trial

A planned U.S. seizure trial faces an FDA partial clinical hold after Bright Minds Biosciences Inc. CNSXDRUG NASDAQDRUG disclosed concerns about mouse toxicity and insufficient pediatric data on Monday. The affected Phase 2 protocol is BMB-101-105, covering its investigational medicine BMB-101.

The Nov. 2 company release says the FDA notified Bright Minds by email about the hold on its developmental and epileptic encephalopathies application and related protocol. The agency cited inadequate pharmacokinetic and juvenile toxicity data to support enrolling children, alongside the mouse findings.

Bright Minds is a small clinical-stage biotechnology company with Canadian and U.S. headquarters developing treatments for neurological and psychiatric disorders. It believes the hold covers only the planned U.S. study and does not affect its other ongoing clinical trials.

The full FDA letter is pending, leaving the detailed requirements and timetable for resolving the hold unsettled. Bright Minds plans to seek clarification and refine the study, while acknowledging that additional data or studies may be required.

Pediatric Data Remain A Barrier

The proposed trial would randomly assign participants to BMB-101 or placebo under double-blind conditions. It would evaluate efficacy and safety as doses rise to a maximum tolerated dose for seizures associated with developmental and epileptic encephalopathies, or DEEs.

Bright Minds disputes the interpretation of the mouse findings. It says its toxicity reports, peer reviewers and independent toxicology experts support its belief that the findings were incidental and unrelated to the drug, and that similar toxicity was absent in other species.

"These are the Company’s beliefs and should not be understood as the FDA findings or as resolving the FDA’s stated concerns," Bright Minds said in the release.

The company reported that approximately 90 people have received BMB-101 across its clinical programs. Its completed adult Phase 2 BREAKTHROUGH study enrolled 24 participants with drug-resistant absence seizures or DEEs, according to the update.

Six DEE patients completed the main treatment period with a median motor-seizure reduction of 63.3 per cent. The release provides no placebo comparison, confidence interval or p value for that subgroup result, which does not establish an effect against control.

Bright Minds reported no drug-related serious adverse events in BREAKTHROUGH. Those adult observations leave the FDA's stated concerns about the evidence supporting pediatric enrollment unresolved.

Seizure Developers Face Different Milestones

Stoke Therapeutics, Inc. NASDAQSTOK is advancing zorevunersen for Dravet syndrome, a DEE. Its Oct. 5 update describes a sham-controlled Phase 3 trial whose primary endpoint measures change in major motor seizure frequency at Week 28, with results expected in the third quarter of 2027.

A separate regulatory comparison is Arbutus Biopharma Corporation NASDAQABUS. It said on Oct. 22 that the FDA lifted its AB-101 clinical hold, permitting further U.S. development, while the company was still evaluating its next steps.

Read more: Arbutus Biopharma says FDA lifts AB-101 clinical hold

Bright Minds reported C$307.8 million in cash and equivalents at June 30 in its August financial filing. Operating activities used C$23.4 million during the nine months ended June 30; the hold announcement supplies no revised cash runway.

Bright Minds shares NASDAQDRUG closed at US$54.98 on Oct. 30 at 4 p.m. EDT, before the hold announcement. For sector context, the iShares Biotechnology ETF NASDAQIBB closed at US$217.61 on Oct. 30 at 4 p.m. EDT.

Bright Minds said on Nov. 2 that the FDA would supply its full letter within 30 days, including study-design recommendations. That letter is the next regulatory milestone; the release gives no date for lifting the hold or starting the U.S. trial.